investor.mateon.comInvestor Overview | Mateon Therapeutics
investor.mateon.com Profile
Investor.mateon.com is a subdomain of mateon.com, which was created on 2004-03-23,making it 20 years ago.
Description：The Investor Relations website contains information about Mateon Therapeutics's business for stockholders, potential investors, and financial...
Discover investor.mateon.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
investor.mateon.com Information
| HomePage size: 71.817 KB |
| Page Load Time: 0.736835 Seconds |
| Website IP Address: 23.208.37.53 |
investor.mateon.com Similar Website
| Exantas Investor Relations - Investor Overview |
| Investor Relations :: Checkpoint Therapeutics, Inc. (CKPT) |
| Investor Relations | TG Therapeutics, Inc. |
| Revance Therapeutics, Inc. - Investor Relations |
| Overview - Regulus Therapeutics |
| Coya Therapeutics - Investor Relations |
| Investor Relations :: BioXcel Therapeutics, Inc. (BTAI) |
| United Therapeutics Investor Relations |
| Mirati Therapeutics Inc. - Investor & Media Relations |
| Investor Relations - Investor Overview |
| Investor Overview NYSE: BW » Babcock & Wilcox Investor |
| Edgewise Therapeutics, Inc. - Investor |
| Cyteir Therapeutics - Investor |
| Halozyme Therapeutics, Inc. - Investor |
investor.mateon.com PopUrls
http://investor.mateon.com/investor-relations |
http://investor.mateon.com/news-releases |
http://investor.mateon.com/news-releases/news-release-details/mateons-c001-global-phase-2-study-ot-101-against-covid-19 |
http://investor.mateon.com/news-releases/news-release-details/mateon-expands-its-covid-19-therapeutic-program-include |
http://investor.mateon.com/news-releases/news-release-details/mateon-develop-its-ot-101-phase-3-clinical-drug-candidate |
http://investor.mateon.com/news-releases/news-release-details/mateon-provides-update-its-rapid-antiviral-response-program |
http://investor.mateon.com/sec-filings/sec-filing/8-k/0001493152-20-020476 |
http://investor.mateon.com/news-releases/news-release-details/mateon-announces-first-patient-enrolled-arti-19-multicenter |
http://investor.mateon.com/node/15336/html |
http://investor.mateon.com/node/14826/html |
http://investor.mateon.com/events-and-presentations |
http://investor.mateon.com/news-releases/news-release-details/mateon-therapeutics-closes-20-million-financing |
http://investor.mateon.com/email-alerts |
http://investor.mateon.com/news-releases/news-release-details/mateon-therapeutics-reports-second-quarter-2020-financial |
http://investor.mateon.com/news-releases/news-release-details/mateons-global-study-artemisinin-intervention-against-covid-19 |
http://investor.mateon.com/news-releases/news-release-details/mateon-participate-bio-investor-forum-digital |
http://investor.mateon.com/news-releases/news-release-details/company-expands-its-management-team-accelerate-commercialization |
http://investor.mateon.com/news-releases/news-release-details/mateon-completes-its-acquisition-pointr-data-inc |
http://investor.mateon.com/news-releases/news-release-details/oxigene-announces-5-million-private-placement |
http://investor.mateon.com/news-releases/news-release-details/mateon-advisor-dr-suhas-kshirsagar-will-present-delhi-university |
http://investor.mateon.com/news-releases/news-release-details/mateon-announces-filing-ind-us-fda-evaluate-its-antisense-drug |
http://investor.mateon.com/news-releases/news-release-details/oxigene-announces-results-stockholder-vote-proposed-merger/ |
investor.mateon.com Httpheader
| Accept-Ranges: bytes |
| Content-Encoding: gzip |
| Content-Language: en |
| Content-Type: text/html; charset=UTF-8 |
| device: desktop |
| ETag: "1607770742" |
| Expect-CT: max-age=0, report-uri="/report-expect-ct-violation" |
| Feature-Policy: "accelerometer none;ambient-light-sensor none;autoplay self;camera none;encrypted-media none;fullscreen self;geolocation self;gyroscope none;magnetometer none;microphone none;midi none;payment none;picture-in-picture none;speaker self;sync-xhr self;usb none;vibrate none;vr none", From-Origin: same |
| Last-Modified: Sat, 12 Dec 2020 10:59:02 GMT |
| Link: http://investor.mateon.com/; rel="shortlink", http://investor.mateon.com/investor-relations/; rel="canonical", http://investor.mateon.com/investor-relations; rel="alternate"; hreflang="en", http://investor.mateon.com/investor-relations; rel="revision" |
| Referrer-Policy: no-referrer-when-downgrade |
| X-Age: 0 |
| X-Content-Type-Options: nosniff |
| X-Drupal-Dynamic-Cache: UNCACHEABLE |
| X-Frame-Options: SAMEORIGIN |
| X-Request-ID: v-0b7fe37c-3c69-11eb-9ed1-e7a426620a03 |
| X-UA-Compatible: IE=edge |
| X-XSS-Protection: 1; mode=block |
| Content-Length: 15158 |
| Cache-Control: public, max-age=0, s-maxage=1800 |
| Expires: Sat, 12 Dec 2020 10:59:03 GMT |
| Date: Sat, 12 Dec 2020 10:59:03 GMT |
| Connection: keep-alive |
| Vary: Accept-Encoding |
| Set-Cookie: DrupalVisitorMobile=0; path=/; Secure; HttpOnly |
investor.mateon.com Meta Info
| charset="utf-8"/ |
| content="Mateon Therapeutics" property="og:site_name"/ |
| content="website" property="og:type"/ |
| content="The Investor Relations website contains information about Mateon Therapeutics's business for stockholders, potential investors, and financial analysts." name="description"/ |
| content="http://investor.mateon.com/investor-relations" property="og:url"/ |
| content="Investor Overview | Mateon Therapeutics" property="og:title"/ |
| content="no-referrer" name="referrer"/ |
| content="The Investor Relations website contains information about Mateon Therapeutics's business for stockholders, potential investors, and financial analysts." property="og:description"/ |
| content="Drupal 8 (https://www.drupal.org)" name="Generator"/ |
| content="width" name="MobileOptimized"/ |
| content="true" name="HandheldFriendly"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
investor.mateon.com Ip Information
| Ip Country: United States |
| City Name: Philadelphia |
| Latitude: 39.9528 |
| Longitude: -75.1646 |
investor.mateon.com Html To Plain Text
COVID-19 ARTIVeda Pipeline EdgePointInvestors Investors & News Investor Overview Press Releases Stock Quote SEC Filings Events & Presentations Investor Contacts Alerts Corporate Governance Contact Home COVID-19 ARTIVeda Pipeline EdgePointInvestors Investors & News Investor Overview Press Releases Stock Quote SEC Filings Events & Presentations Investor Contacts Alerts Corporate Governance Contact Enter your keyword Search Efficiently Creating Value with Innovative Science Investors & News Investor Overview Press Releases Stock Quote SEC Filings Events & Presentations Investor Contacts Alerts Corporate Governance Day High: Day Low: Volume: 8:03 PM EST Dec 09, 2020 Data Provided by Refinitiv. Minimum 15 minutes delayed. Intra 3 mo. 6 mo. 1 yr. Investor Overview We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide. We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders. Our common stock is traded on the OTCQB Market under the symbol MATN”. POSITIVE EARLY RESULTS FOR ARTIVEDA TM IN TREATING COVID-19. Download this Report (PDF 480 KB) Click HERE for Stonegate analyst report. Click HERE for Zacks SCR analyst report. Click HERE for Litchfield Hills Research analyst report. We are headquartered in Agoura Hills, California. Learn More Jun 15, 2020 2019 Annual Report 966.4 KB Press Releases Dec 09, 2020 MATEON TO HOST VIRTUAL WEBINAR ADDRESSING COVID-19 AND THERAPIES AYURVEDA AND ARTEMISIA ON DECEMBER 16, 2020 Nov 30, 2020 DEVELOPMENT UPDATE FOR ARTIVEDA™/ARTISHIELD™ AGAINST COVID-19 View all press releases Events & Presentations Oct 13 - Oct 15, 2020 BIO Investor Forum Digital View all events & presentations Shareholder Tools Email Alerts Email Alerts Downloads Downloads Print Print Share Share Search Search Facebook LinkedIn Twitter RSS About Mateon Mateon Therapeutics is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in orphan oncology indications. VTTs include vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA approved and widely used in cancer treatment. These 2 approaches (VDAs and AAs) have distinct yet complementary mechanisms of action. At Mateon, we believe that we can significantly improve cancer therapy by combining these 2 complementary approaches. Links Home COVID-19 Pipeline EdgePointInvestors Contact Our Office Mateon Corporate Headquarters 29397 Agoura Road, Suite 107 Agoura Hills, CA 91301 info@mateon.com (650) 635-7000 (650) 635-7001 Copyright © 2020 Mateon Therapeutics, Inc., Terms and Privacy...
investor.mateon.com Whois
Domain Name: MATEON.COM Registry Domain ID: 114956499_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2022-09-21T06:16:26Z Creation Date: 2004-03-23T23:44:48Z Registry Expiry Date: 2026-03-23T22:44:48Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS21.DOMAINCONTROL.COM Name Server: NS22.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T21:05:50Z <<<